ACOG Stock Price, Analysis & Fundamentals | Alpha Cognition Inc. Common Stock

Analysis

Alpha Cognition Inc. Common Stock operates in the Healthcare sector, specifically within the Biotechnology industry. Market capitalization stands at $134.15M. Financially, Alpha Cognition Inc. has reported a gross margin of 76.9%, an operating margin of -187.0%, and a profit margin of -262.2%. The company's returns on equity (ROE) and assets (ROA) were -125.7% and -42.2%, respectively. Alpha Cognition Inc. maintains $35.40M in cash, with no reported debt. The valuation context for Alpha Cognition Inc. includes a forward P/E of -6.56, a price to book ratio of 2.96, and a price to sales ratio of 18.06. Additionally, the EV/EBITDA is -6.13.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Alpha Cognition Inc. Common Stock

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Visit website →

ACOG

Price History (1Y)

Analysis

About Alpha Cognition Inc. Common Stock

Key Statistics

Company Info